I guess you could say that the Stanford Biodesign Program “wrote the book” on how to teach medical technology innovation to multidisciplinary teams. The U.S. Food and Drug Administration recently acknowledged the effectiveness of this training program by signing a “memorandum of understanding with Stanford, which I discuss in todays Inside Stanford Medicine.
The agreement lays the groundwork for the FDA and Stanford to collaborate on a number of initiatives, including educational outreach, cross-training of scientific personnel, and the development of new biostatistical methods for more accurately evaluating the safety of emerging medical technologies.
The biodesign program, which is in its 11th year, trains teams of doctors, engineers and business students — in an intensive one-year program — to identify a medical need, develop an invention to fill it, create a business plan, navigate the regulatory process, then present their inventions to venture capitalists. Since its inception, the program has led to more than 200 patents and 24 start-up companies.
Similar Posts:
- Grand Roundup: Top posts for the week of Aug. 21
- 4 Non-Labor Intensive Jobs in the Oil Industry
- UCR’s Chancellor White Has Complications from Recent Heart Procedure
- EA Solutions For Resolving Employer Errors With Retirement Plans
- Pay Attention When Scott Adams Gives Education Advice to College Students
